Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation

Keyphrases

• Molecular Subgroups 100%
• Metagenomic Next-generation Sequencing (mNGS) 100%
• Head-and-neck 100%
• Squamous Cell Carcinoma of Head 100%
• Concurrent Chemoradiation 100%
• HPV Status 80%
• Tumor Protein p53 (TP53) 60%
• Notch1 60%
• Somatic mutation 40%
• Clinical Factors 40%
• Phosphoinositide 3-kinase (PI3K) 40%
• Risk Stratification 40%
• Locally Advanced 40%
• Mutational Profile 40%
• Mutational Profiling 40%
• Receptor Tyrosine Kinase 40%
• Germline Variants 40%
• Nonsynonymous 20%
• All Genetics 20%
• Germline mutation 20%
• Genetic Markers 20%
• Patient Subgroups 20%
• N Stage 20%
• Prognostic Value 20%
• Prognostic Relevance 20%
• Tumor Specimens 20%
• Clinical High Risk 20%
• High-risk Population 20%
• Clinical Risk Factors 20%
• Risk Classification 20%
• Smoking Habits 20%
• Improved Outcomes 20%
• Multivariate Model 20%
• Risk Model 20%
• Biomarker Studies 20%
• Prognosticator 20%
• Independent Risk Factors 20%
• Kinase Receptors 20%
• P53 Pathway 20%
• Hypopharynx 20%
• Hypopharyngeal Carcinoma 20%
• P16 Immunohistochemistry 20%
• Randomized Phase III Trial 20%
• Intermediate-risk Group 20%
• Low-risk Group 20%
• HPV DNA 20%
• Advanced Oropharyngeal Carcinoma 20%
• Rs1870377 20%
• Oropharynx Squamous Cell Carcinoma 20%

Biochemistry, Genetics and Molecular Biology

• Next Generation Sequencing 100%
• Germline 40%
• Somatic Mutation 40%
• High Risk Population 40%
• Phosphoinositide 3-Kinase 40%
• Receptor Tyrosine Kinase 40%
• Germ Cell 40%
• Genetic Marker 20%
• Immunostaining 20%
• Biomarker Study 20%
• Oropharynx 20%
• Hypopharynx 20%
• P16 20%
• Germline Mutation 20%
• Low Risk Population 20%
• Smoking Habit 20%
• Intermediate Risk Population 20%
• P53 20%
• Phase III Trials 20%